Novastem Treats First Patient Using Stemedica’s Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke

Novastem is dedicated to the study and research of regenerative medicine and has now treated their first patient for ischemic stroke at their facilities. Novastem’s study is called “Internal Research Protocol in Combination Therapy of Intravenous Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal Administration of Neural Stem Cells in Patients with Motor Aphasia due to Ischemic Stroke.” and uses a combination therapy using stem cells owned by Stemedica Cell Technologies.

Read more about this breakthrough treatment here: